Business intelligence reports for the lab diagnostics industry
Subscribe for Exclusive Access.
Subscriptions & Reports
Interested in multiple copies or more than one of our G2 reports?
Call Sokha at 855-528-6903 or email spearson@g2intelligence.com to discuss pricing.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
Advancements in Antimicrobial Susceptibility Testing: Part 1
A brief overview of antimicrobial susceptibility testing, current methods used, and new methods on the horizon.
Polygenic Risk Scores: A Cardiovascular Conundrum
Polygenic risk scores may offer new screening and risk stratification options for cardiovascular disease—but how valuable are they?
Expert Q&A: Enhancing Clinical Labs through Advanced Data Analytics
Lisa-Jean Clifford of Gestalt Diagnostics, discusses key trends, challenges, and solutions in data analytics for clinical labs.
Lost Ground: Cancer Screening in the COVID-19 Era
A pandemic-related drop in cancer diagnoses could spell long-term trouble for patients and providers.
Patient-Centric Strategies for Labs: A Roadmap for 2024
Five strategies for lab leaders to focus on to tackle the challenges of today and ensure future success.
OSHA Citations for Hazardous Chemicals in Labs May Stem from Subpar Training
Standard 1910.1450 requires labs to have a chemical hygiene plan.
Laboratory Safety: A Universal Right
Approaching laboratory safety from a diversity, equity, inclusion, and accessibility perspective.
AI: With the Lab Every Step of the Way
Artificial intelligence models have a valuable role to play in each phase of the total testing process.
FDA Watch: Agency Opens New Pathway for STI At-Home Sample Collection Kits
With US STI cases continuing to climb to numbers not seen in decades, a recent FDA approval comes at an opportune moment.
Roche & Quest Establish Toeholds in Emerging Alzheimer’s Blood Testing Market
While Roche has an early lead, Quest recently made key moves to improve its position in the AD patient-initiated blood testing market.